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Closed loop insulin systems use a glucose sensor and insulin delivery system to maintain                         
the blood glucose levels in an automated manner. These devices show great promise as a                           
potential treatment option more importantly for Diabetes Mellitus Type 1 but also, Diabetes                       
Mellitus Type 2. However these devices face many problems and these need to be solved                           
before a truly clinically applicable form of the device is commercially introduced. Their                       
efficacy also needs to be improved in certain groups such as children and pregnant women.                           
The literature search was done on two indexes, Google Scholar and PubMed, using mesh                         
words ‘closed loop insulin delivery in diabetes’. All the publications, by various authors,                       
returning to this search, were critically reviewed, assimilated and summarized. This article                     
presents this summary of the problems faced by these devices and suggests possible                       
solutions for their improvement.
Introduction
Type 1 diabetes (T1D) is characterized by immune mediated pancreatic beta cell                     
destruction, thus absolute insulin deficiency. It predominantly affects the youth, with an                     
increasing rate in the last decades (1). Patients with T1D, their families and care providers                           
face the challenge of maintaining blood glucose levels in the near to normal range over years,                             
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which has been proved to be important for prevention of long­term microvascular and                       
macrovascular complications (2) and to avoid the acute complications of severe                   
hypoglycemia (SH) and diabetic ketoacidosis.
Infusion of insulin during the treatment of DMT1 may lead to hypoglycemic episodes since                         
continuous manual monitoring of the blood glucose levels and adjustment of insulin dose                       
accordingly is not feasible (3). Variability resulting from differences in patient compliance may                       
decrease the overall efficacy of the treatment regimens (4).
The never­ceasing challenge faced by diabetic patients and their caregivers has through the                       
years inspired continuing efforts to find ways and means for achieving better control of blood                           
glucose levels. The new modern advanced technologies of closed­loop devices aims to                     
mimic the human pancreas by continuous measurement of blood glucose and releases the                       
amount of insulin accordingly. Some devices are also capable of reversing hypoglycemia by                       
infusing hyperglycemic solutions in place of insulin (5). Improved glycemic control and lower                       
rates of hypoglycemia and nocturnal hypoglycemia have been reported with these devices                     
(6).
Another, aspect of closed loop insulin­delivery comprises of real time continuous glucose                     
monitoring (RT­CGM). Frequent blood glucose tests per day were shown to be an important                         
factor related to metabolic control in patients with T1D (7). Standard use of glucose meters                           
for self­monitoring of blood glucose (SMBG) provides only intermittent single blood glucose                     
levels without illustrating the glucose variability during the 24 h. Therefore, the use of                         
RT­CGM provides continuous glucose measurements which may have potential to increase                   
the proportion oo patients who are able to maintain target HbA1c values, to decrease glucose                           
excursions and to decrease the risk of SH.
This paper reviews current research into the development of a closed loop insulin delivery                         
system, with particular emphasis on creating a system emulating the physiological properties                     
of the beta­cell.
Discussion: Limitations, and Future Directions
An artiﬁcial Beta­cell requires a glucose sensor, an insulin­delivery pump, and an algorithm                       
for calculating insulin delivery. Technological and scientiﬁc advances have made sensors                   
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and pumps available, but linking the two as a “closed loop” has been challenging (8).                           
Lingering questions remain regarding the suitability of different glucose­sensing sites                 
(subcutaneous versus intravascular), insulin­delivery sites (subcutaneous versus           
intravascular versus intraperitoneal), and sensor reliability. In addition, no one algorithm has                     
been universally accepted as optimal for insulin delivery (9).
Most of the currently available devices employ a single sensor for blood glucose monitoring.                         
A single sensor has a high risk of inaccuracy resulting from calibration error or current drift                             
(10). Use of two blood glucose monitors decreases the chance of such errors. Other                         
limitations of the devices include physiological time lag and interference of the sensors with                         
non­glucose substances and thus giving false results (11).
Corticosteroids especially have a tendency to interfere with the functioning of the device by                         
reducing insulin sensitivity and causing stress­induced hyperglycemia. A similar               
hyperglycemic state is also observed in acute infections occurring in patients with diabetes.
The physiological time lag is one of the greatest challenges to these devices. Even the                           
fastest acting insulin analogs available today are not fast enough to remove this barrier. New                           
pharmacological developments are required to either increase the rate of absorption of insulin                       
analogs or develop insulin analogs that can bring an effect even faster than current insulin                           
analogs (12). Otherwise an intraperitoneal insulin delivery system may be used. Insulin                     
delivered via intraperitoneal route may reduce the physiological time lag to a quarter (13).                         
However catheter related complications may develop with this route of insulin delivery. If such                         
developments do come into existence, these devices will lead to a more optimal blood                         
glucose control.
Unpredictable eating and exercise patterns in patients, especially children, pose a risk for                       
hypoglycemia (14). Until better sensors are developed and the problem of physiological time                       
lag countered, it might be more prudent to use semi­automatic devices that may be switched                           
off at will. Such inclusions are necessary to prevent hypoglycemic episodes especially at                       
night and after exercise.
The above mentioned two problems of physiological time lag and haphazard food habits can                         
be dealt effectively with closed loop delivery systems that continuously sense blood glucose                       
levels (RT­CGM) and accordingly alter the dose of insulin injected.
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The sensors on current devices use the subcutaneous interstitial space to measure the                       
glucose levels (15). This method is not only comparatively inaccurate but also contributes to                         
the time lag. Therefore current devices require manual adjustment of the dose of insulin                         
when the intrinsic body insulin or glucose load changes rapidly such as in times of food                             
intake and stress.
As compared to the effects of these devices of non­pregnant individuals with DMT1, the                         
efficacy of these systems in pregnant women is not well­established. Some studies have                       
shown these systems to be safe and effective during pregnancy (16). However due to certain                           
physiological changes in pregnancy, such as changes in the production and metabolism of                       
glucose and insulin, the efficacy of these devices in pregnant women remains lower as                         
compared to that in non­pregnant individuals (16, 17). More work is needed to eliminate the                           
periods of hyperglycemia seen during pregnancy and to achieve optimal postprandial glucose                     
levels comparable to that seen without pregnancy.
Also, these devices, especially those based on continuous subcutaneous insulin infusion                   
lead to extensive insulin regimens and thus increase the Total Daily Dose (TDD) of insulin.                           
(18)
The patient needs to be advised against rough sports, especially contact sports, and other                         
activities which may physically damage the device. Wearing the device at all times may also                           
be seen by many patients as uncomfortable. Combining insulin delivery and continuous                     
glucose sensing into a single device is likely to increase device acceptability and hence                         
compliance with wear. Work on devices that can be implanted subcutaneously with                     
non­invasive procedures of refilling the insulin and glucagon stores is being done.
All large scale clinical studies performed to assess the safety and efficacy of such systems                           
have been in highly controlled environment (19). Studies in such highly controlled                     
environments are only poorly applicable to the daily environment of patients. Therefore long                       
term safety and efficacy trials should be conducted in a range of patients in uncontrolled                           
environments.
It is known earlier that diabetes increases one’s risk for depression (20); therefore, targeting                         
depression would seem to be a vital psychosocial variable to include in future such device                           
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assessments. Other areas of psychosocial functioning that are important to assess include                     
measurements of self­management (21–23), quality of life (24), family functioning (25), and                     
patient­provider relationships (26). Recently it has been shown that patient acceptance of                     
future use of a closed­loop system is likely to be positive based on qualitative evaluation in                             
adult patients (27), and caregivers of children with type 1 diabetes (28).
Before the currently available devices can be used commercially, it is imperative that the                         
overall cost of manufacturing and the size of the device be adjusted to suit the users. If that                                 
can be achieved, we can hypothesize that the coming generation might not see DMT1 as a                             
lifelong disease which severely affects the quality of life but as a simple curable disease                           
requiring only the installation of an easy to operate, cost effective device.
In the last 3 years, it has been demonstrated that telemedicine may play an increasing role in                               
closed­loop systems, enabling remote monitoring and logging of data. A prototype closed                     
loop device equipped with global positioning system technology has been proposed as a way                         
of alerting family and medical personnel of the location of patients in the event of severe or                               
impending hypoglycemia (29).
Prior to employment of closed­loop systems in clinical practice, strict safety checks by                       
regulatory bodies are essential. Ongoing safety monitoring in addition to robust infrastructure                     
to manage technical issues will be necessary.
Conclusion
The ‘artificial pancreas’ or the closed – loop delivery system may offer a more convenient and                             
superior mode of insulin delivery. They can potentially help us achieve near – normal and                           
even physiological glucose profiles. Introduction of closed­loop insulin delivery into clinical                   
practice is likely to be gradual. Just as it has taken a long time to reach the stage where we                                     
can actually foresee the development of a clinically applicable closed loop device, there is still                           
a long time to go before these devices can be commercialized and be offered to patients as a                                 
routine treatment option.
Further research is required to address the current hurdles of physiological time lag,                       
hypoglycemic episodes, sub­optimal blood glucose control in children and pregnant women,                   
encountered in closed loop device functioning, including refinement of control algorithms to                     
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cope with variability in insulin requirements and development of more accurate glucose                     
sensors.
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